Stand out for this role — generate a tailored resume and cover letter in about a minute.
University of Oslo invites a highly motivated PhD candidate to join the DC12 project on small-molecule promoters of inflammation resolution. The research integrates computational experiments with medicinal chemistry and will involve collaboration with networks across the field.
The doctoral work includes synthesis, biological evaluation, and data interpretation, contributing to potential therapies for inflammatory diseases, and coordinating with both academic and industrial partners.
Organisation/Company University of Oslo Research Field Pharmacological sciences Researcher Profile First Stage Researcher (R1) Positions PhD Positions Application Deadline 1 Oct 2026 - 23:00 (Europe/Oslo) Country Norway Type of Contract Temporary Job Status Full-time Hours Per Week 37.5 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
We are looking for a highly motivated PhD candidate to join our team at the Uni-versity of Oslo for the project: DC12 - Small-molecule promoters of inflammation resolution.
This project aims to develop low-molecular-weight resolution promoters targeting GPR101 as potential therapies for rheumatoid arthritis. Computational experiments will guide compound design, synthesis, and biological evaluation, including the assessment of bioactivity, mechanisms of action, medicinal chemistry properties, and metabolism.
The work will be conducted in close collaboration with research groups across the network working on resolution biology and drug discovery based on resolution pharmacology. The position also include internships with both academic and industrial partners, and the doctoral candidate must participate in these activities.
Methods will include synthetic medicinal chemistry, chromatography, spectroscopic and analytical techniques (HPLC, LC-MS, and GC), as well as computational tools. An integral part of the work will be the integration of biological data with medicinal chemistry principles to identify the most promising molecular candidates.